Skip to content

A Novel Concept for Continuous Peripheral Nerve Block - Sciatic Nerve

A Novel Concept for Continuous Peripheral Nerve Block - Popliteal Region

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02456597
Enrollment
16
Registered
2015-05-28
Start date
2015-04-30
Completion date
2015-06-30
Last updated
2015-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Peripheral Nerve Blocks

Brief summary

To investigate the function of a novel catheter for continuous peripheral nerve blocks in the popliteal nerve: Two key issues are investigated 1) Successful primary placement and function of the catheter for continuous peripheral nerve blocks confirmed by a decrease in motor function following injection of local analgesics through the catheter; 2) The rate of displacement after standardized movement of the limb where the catheter for continuous peripheral nerve blocks is inserted.

Detailed description

Although peripheral nerve blocks are known to provide superior postoperative analgesia. Continuous peripheral nerve block (CPNB) are not used to the extent they deserve. This is predominantly due to variable success rates. Furthermore, the existing techniques for placing catheters for CPNBs are technically complicated and time consuming.4,5 Major problems include difficult insertion of the catheter tip past the needle, difficult visualization of catheter advancement, secondary displacement of the local anesthetic (LA) injection orifice(s) and limited possibility of repositioning the catheter once it has been left in situ. We have developed a new catheter for CPNBs to address and overcome these limitations. Hence, the new catheter should primarily provide precise initial placement of the catheter, less risk of secondary displacement and a possibility to readjust the new catheter at any time point after initial placement. Furthermore, in-plane ultrasound (US) visualization during the entire procedure and during readjustment should be possible. The new catheter should also provide a simple and rapid technique with few components. Initial proof of concept studies in cadavers are promising with success rates close to 100 % both for initial placement and readjustment

Interventions

DRUGlidocainhydrochlorid

Lidocaine injected through the novel Catheter

DRUGIsotonic Saline

Isotonic saline injected through the novel Catheter

Sponsors

Kai Henrik Wiborg Lange
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Male or female ≥18 years of age at Visit X. 2. ASA classification ≤ II 3. Written informed consent obtained from volunteer and ability for volunteer to comply with the requirements of the study.

Exclusion criteria

1. BMI ≥ 30 2. Previous or ongoing surgery, pain or other disability of investigated region. 3. Prescriptive drugs other than anti-contraceptive. 4. Sensory or neurologic deficits in the investigated region 5. Allergy to LA 6. Pregnancy, breastfeeding, or unwilling to practice birth control during participation in the study.-

Design outcomes

Primary

MeasureTime frameDescription
Muscle force (dynamometer) change from baselinean average of three monthsDecreased muscle force measured with a dynamometer after intervention

Secondary

MeasureTime frameDescription
Displacement of catheter (mm) change from initial placementan average of three monthsDisplacement of catheter in millimeters assessed by ultrasound
Surface EMG (sEMG) change from baselinean average of three monthsDecreased EMG response (mV) after intervention
Cutaneous Sensory Mapping (Decreased sensibility in the region innervated by Tibial and Popliteal nerves) change from baselinean average of three monthsDecreased sensibility in the region innervated by Tibial and Popliteal nerves

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026